Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tildrakizumab (Primary)
  • Indications Plaque psoriasis; Psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Sun Pharma Global FZE; Sun Pharmaceutical Industries

Most Recent Events

  • 06 Jun 2025 Status changed from active, no longer recruiting to completed.
  • 07 Mar 2025 According to Sun Pharmaceutical Media Release, Primary endpoint (The proportion of subjects who achieve at least a 75% improvement from baseline in totalmNAPSI at Week 28.) has been met.
  • 07 Mar 2025 According to Sun Pharmaceutical Media Release, company announced results describing significance of ILUMYA in patients with nail psoriasis severity compared to placebo

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top